Segmentation by type distinguishes the delivery formats that shape the sodium cantharidinate market’s structural composition. The injectable format, predominantly supplied as a lyophilized powder reconstituted for intravenous infusion, commands the highest share, estimated at 45 %, due to its suitability for controlled dosing in oncology and acute infection settings. Oral formulations, including enteric‑coated tablets and capsules, represent roughly 30 % of the market; they are favored for chronic dermatologic indications where patient compliance and convenience are paramount. The topical category, encompassing creams, gels, and ointments, contributes about 20 % and is driven by dermatology’s demand for localized therapy with minimal systemic exposure. A residual 5 % is attributed to research‑grade preparations, such as high‑purity powders used in preclinical studies, which, while small in volume, support pipeline development and influence overall market dynamics. Each type’s proportion reflects regulatory pathways, clinical usage patterns, and manufacturing complexity, collectively informing strategic positioning within the broader market taxonomy.
